Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009;23:1142–1150.
-
2. Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 2008;22:120–128.
-
3. Hori Y, Ukai Y, Uechi M, et al. Relationships between velocities of pulmonary venous flow and plasma concentrations of atrial natriuretic peptide in healthy dogs. Am J Vet Res 2008;69:465–470.
-
4. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24:341–356.
-
5. Remppis A, Ehlermann P, Giannitsis E, et al. Cardiac troponin T levels at 96 hours reflect myocardial infarct size: a pathoanatomical study. Cardiology 2000;93:249–253.
-
6. Voss EM, Sharkey SW, Gernert AE, et al. Human and canine cardiac troponin T and creatine kinase-MB distribution in normal and diseased myocardium. Infarct sizing using serum profiles. Arch Pathol Lab Med 1995;119:799–806.
-
7. Hori Y, Yamano S, Iwanaga K, et al. Evaluation of plasma C-terminal atrial natriuretic peptide in healthy cats and cats with heart disease. J Vet Intern Med 2008;22:135–139.
-
8. Hori Y, Yamano S, Kanai K, et al. Clinical implications of measurement of plasma atrial natriuretic peptide concentration in dogs with spontaneous heart disease. J Am Vet Med Assoc 2011;239:1077–1083.
-
9. Langhorn R, Tarnow I, Willesen JL, et al. Cardiac troponin I and T as prognostic markers in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2014;28:1485–1491.
-
10. Winter RL, Saunders AB, Gordon SG, et al. Analytical validation and clinical evaluation of a commercially available high-sensitivity immunoassay for the measurement of troponin I in humans for use in dogs. J Vet Cardiol 2014;16:81–89.
-
11. Oosterhof T, Tulevski II, Vliegen HW, et al. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am J Cardiol 2006;97:1051–1055.
-
12. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464–469.
-
13. Hori Y, Ohshima N, Chikazawa S, et al. Myocardial injury-related changes in plasma NT-proBNP and ANP concentrations in a canine model of ischemic myocardial injury. Vet J 2012;191:46–51.
-
14. Chun R, Kellihan HB, Henik RA, et al. Comparison of plasma cardiac troponin I concentrations among dogs with cardiac hemangiosarcoma, noncardiac hemangiosarcoma, other neoplasms, and pericardial effusion of nonhemangiosarcoma origin. J Am Vet Med Assoc 2010;237:806–811.
-
15. Falk T, Ljungvall I, Zois NE, et al. Cardiac troponin-I concentration, myocardial arteriosclerosis, and fibrosis in dogs with congestive heart failure because of myxomatous mitral valve disease. J Vet Intern Med 2013;27:500–506.
-
16. Porciello F, Rishniw M, Herndon WE, et al. Cardiac troponin I is elevated in dogs and cats with azotaemia renal failure and in dogs with non-cardiac systemic disease. Aust Vet J 2008;86:390–394.
-
17. Langhorn R, Willesen JL, Tarnow I, et al. Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I. Vet Clin Pathol 2013;42:490–498.
-
18. Winter RL, Saunders AB, Gordon SG, et al. Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays. Vet Clin Pathol 2017;46:299–307.
-
19. Polizopoulou ZS, Koutinas CK, Dasopoulou A, et al. Serial analysis of serum cardiac troponin I changes and correlation with clinical findings in 46 dogs with mitral valve disease. Vet Clin Pathol 2014;43:218–225.
-
20. Boswood A, Haggstrom J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study—a randomized clinical trial. J Vet Intern Med 2016;30:1765–1779.
-
21. Gordon SG, Saunders AB, Wesselowski SR. Asymptomatic canine degenerative valve disease: current and future therapies. Vet Clin North Am Small Anim Pract 2017;47:955–975.
-
22. Buchanan JW, Bücheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194–199.
-
23. Hamlin RL. Analysis of the cardiac silhouette in dorsoventral radiographs from dogs with heart disease. J Am Vet Med Assoc 1968;153:1446–1460.
-
24. Cornell CC, Kittleson MD, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311–321.
-
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845.
-
26. Biondo AW, Liu ZL, Wiedmeyer CE, et al. Genomic sequence and cardiac expression of atrial natriuretic peptide in cats. Am J Vet Res 2002;63:236–240.
-
27. Rishniw M, Barr SC, Simpson KW, et al. Cloning and sequencing of the canine and feline cardiac troponin I genes. Am J Vet Res 2004;65:53–58.
-
28. Greco DS, Biller B, Van Liew CH. Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 2003;44:293–297.
-
29. Katrukha A, Bereznikova A, Filatov V, et al. Biochemical factors influencing measurement of cardiac troponin I in serum. Clin Chem Lab Med 1999;37:1091–1095.
-
30. Asano K, Masuda K, Okumura M, et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999;61:523–529.
-
31. Häggström J, Hansson K, Kvart C, et al. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease. J Vet Cardiol 2000;2:7–16.
-
32. Lang CC, Choy AM, Turner K, et al. The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man. J Hypertens 1993;11:737–741.
-
33. Wambach G, Koch J. BNP plasma levels during acute volume expansion and chronic sodium loading in normal men. Clin Exp Hypertens 1995;17:619–629.
-
34. Ljungvall I, Höglund K, Tidholm A, et al. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs. J Vet Intern Med 2010;24:153–159.
-
35. Hezzell MJ, Boswood A, Chang YM, et al. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease. J Vet Intern Med 2012;26:302–311.
-
36. O'Brien PJ, Dameron GW, Beck ML, et al. Differential reactivity of cardiac and skeletal muscle from various species in two generations of cardiac troponin-T immunoassays. Res Vet Sci 1998;65:135–137.
-
37. Surachetpong S, Jiranantasak T, Rungsipipat A, et al. Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves. J Vet Cardiol 2013;15:171–180.
-
38. Fonfara S, Loureiro J, Swift S, et al. Cardiac troponin I as a marker for severity and prognosis of cardiac disease in dogs. Vet J 2010;184:334–339.
-
39. Hamacher L, Dorfelt R, Muller M, et al. Serum cardiac troponin I concentrations in dogs with systemic inflammatory response syndrome. J Vet Intern Med 2015;29:164–170.
-
40. Sjöstrand K, Wess G, Ljungvall I, et al. Breed differences in natriuretic peptides in healthy dogs. J Vet Intern Med 2014;28:451–457.
Advertisement
Evaluation of atrial natriuretic peptide and cardiac troponin I concentrations for assessment of disease severity in dogs with naturally occurring mitral valve disease
Abstract
OBJECTIVE
To evaluate and compare the clinical usefulness of plasma atrial natriuretic peptide (ANP) and cardiac troponin-I (cTnI) concentrations for assessment of disease severity in dogs with naturally occurring mitral valve disease (MVD).
ANIMALS
316 dogs with MVD and 40 healthy control dogs.
PROCEDURES
Each dog underwent a physical examination and echocardiographic and thoracic radiographic assessments. Blood samples were obtained and processed for measurement of plasma ANP and cTnI concentrations. Dogs with MVD were categorized into 3 groups (stages B1 [no clinical signs or evidence of cardiac enlargement], B2 [no clinical signs with evidence of cardiac enlargement], and C [history of congestive heart failure and pulmonary edema]) on the basis of American College of Veterinary Internal Medicine guidelines. Receiver operating characteristic curve analysis was used to evaluate the accuracy of plasma ANP and cTnI concentrations for assessment of MVD severity.
RESULTS
Plasma ANP and cTnI concentrations increased as disease severity increased. Median plasma ANP concentrations for all 3 MVD groups and median plasma cTnI concentrations for the stage B2 and C groups were significantly greater than the corresponding concentrations for the control group. Plasma ANP concentration, but not cTnI concentration, appeared to be useful for detection of dogs with subclinical (stages B1 and B2) MVD, whereas both concentrations appeared useful for detection of dogs with stage C MVD.
CONCLUSIONS AND CLINICAL RELEVANCE
Results indicated that plasma ANP and cTnI concentrations should not be used independently to diagnose MVD but can be used to assess MVD severity and supplement echocardiographic findings.
Contributor Notes
Powered by PubFactory